Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Aug 19, 2025, 07:08 ET Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study
Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 medication that is FDA-approved for different indications
Approval ensures that the treatment has undergone rigorous testing for safety and effectiveness, with standardized dosing protocols in place
They may have different concentrations
